FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context
Summary: Background: Currently, assessment of candidate pharmacotherapies in patients with non-alcoholic steatohepatitis (NASH) involves invasive liver biopsy. Non-invasive scores, such as the FibroScan-aspartate aminotransferase (FAST) score, are used to identify candidates for therapy, but their...
Hlavní autoři: | Vincent Wai-Sun Wong, Quentin M. Anstee, Louise M. Nitze, Anja Geerts, Jacob George, Victor Nolasco, Mette S. Kjær, Steen Ladelund, Philip N. Newsome, Vlad Ratziu |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
Elsevier
2023-12-01
|
Edice: | EClinicalMedicine |
Témata: | |
On-line přístup: | http://www.sciencedirect.com/science/article/pii/S258953702300487X |
Podobné jednotky
-
Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
Autor: Evgenia Koureta, a další
Vydáno: (2024-02-01) -
Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective study
Autor: Parth Shah, a další
Vydáno: (2024-02-01) -
Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
Autor: Jae Seung Lee, a další
Vydáno: (2022-04-01) -
Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Autor: Magdalena Mazurek, a další
Vydáno: (2023-02-01) -
The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
Autor: Alexander Chaidez, a další
Vydáno: (2022-11-01)